Defunct Company
Total Trials
1
As Lead Sponsor
0
As Collaborator
Total Enrollment
200
NCT05074121
NAC for Attenuation of COVID-19 Symptomatology
Phase: Phase 2
Role: Collaborator
Start: Mar 31, 2024
Completion: Feb 1, 2025